OKYO Pharma Ltd Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by OKYO Pharma Ltd on July 23, 2026. The filing serves to disclose a specific corporate event rather than providing periodic financial results. The registrant is a foreign private issuer reporting under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a transaction involving company leadership and does not contain audited or unaudited financial statements.
Material Changes and Corporate Actions
The primary material event disclosed is an open market purchase of company stock by the Chief Executive Officer:
- Executive: Robert J. Dempsey, Chief Executive Officer.
- Transaction: Purchase of 15,000 ordinary shares.
- Price: $1.54 per share.
- Market: NASDAQ.
- Date: July 23, 2026.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. The document explicitly states that the attached news announcement (Exhibit 99.1) is furnished and not deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the total number of shares held by Robert J. Dempsey following this transaction to assess total insider ownership.
- Confirm the current trading price of OKYO Pharma shares on NASDAQ relative to the $1.54 purchase price.
- Review the attached Exhibit 99.1 for any additional context regarding the CEO's rationale for the purchase.
- Check subsequent filings for any related insider trading plans (Rule 10b5-1) or further executive transactions.